For US Healthcare Professionals Only
Filter
Interim Results from an International Multicenter Observational Study of Real-World Bimekizumab Treatment of Psoriatic Arthritis
An Interim Analysis of Health-Related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Axial Spondyloarthritis Initiating Bimekizumab in Real-World Clinical Practice
Markers of IL-17 Signaling in the Blood of Patients with Psoriatic Arthritis with Inadequate Response to Tumor Necrosis Factor Inhibitors
Bimekizumab Long-Term Efficacy and Safety in Patients with Psoriatic Arthritis with Baseline Plaque Psoriasis/Nail Involvement to 3 Years
Bimekizumab in Patients with Psoriatic Arthritis Resulted in Sustained Efficacy Assessed Using Composite Outcome Measures to 3 Years